Lipid Lowering Drugs: Present Status and Future Developments
AbstractPurpose of reviewBased on the recent data of the DA VINCI study, it is clear that, besides utilization of statins, there is a need to increase non-statin lipid lowering approaches to reduce the cardiovascular burden in patients at highest risk.Recent findingsFor hypercholesterolemia, the small synthetic molecule bempedoic acid has the added benefit of selective liver activation, whereas inclisiran, a hepatic inhibitor of the PCSK9 synthesis, has comparable effects with PCSK9 monoclonal antibodies. For hypertriglyceridemia, cardiovascular benefit has been achieved by the use of icosapent ethyl, whereas results with ...
Source: Current Atherosclerosis Reports - March 10, 2021 Category: Cardiology Source Type: research
Polypills in Cardiovascular Disease Prevention: Mass-Strategy Approach, Precision Medicine, or an Essential Intertwine Between Them?
AbstractPurpose of ReviewThis review considers the framework of high-risk vs. population approaches as proposed in the Rose ’s axiom within the context of cardiovascular diseases, including its benefits and limitations. We also contextualize the use of precision medicine in primary prevention therapy and contrast that with population approach.Recent FindingsAlthough the high-risk strategy aims at individualized care, the complexity of pharmacologic regimens and other limitations reduces its real-life impact. On the other hand, broad population strategies include treatment of a substantial number of low-risk individuals w...
Source: Current Atherosclerosis Reports - March 10, 2021 Category: Cardiology Source Type: research
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome
AbstractPurpose of ReviewCardiometabolic syndrome is characterized by abdominal adiposity, insulin resistance, hypertension, and dyslipidemia. There is a growing burden of cardiometabolic disease in many parts of the world. This review highlights the critical preventive and therapeutic measures that need to be implemented to reduce the impact of cardiometabolic syndrome on cardiovascular health.Recent FindingsRecent cardiovascular outcome trials demonstrated that newer glucose-lowering medications reduce cardiovascular and renal events in patients with type 2 diabetes mellitus (T2DM). These medications should be considered...
Source: Current Atherosclerosis Reports - March 9, 2021 Category: Cardiology Source Type: research
LDL Apheresis and Lp (a) Apheresis: A Clinician ’s Perspective
AbstractPurpose of ReviewLipoprotein apheresis is the most effective means of lipid-lowering therapy. However, it ’s a semi-invasive, time consuming, and chronic therapy with variable adherence. There are still no specific guideline recommendations for the management of patients on lipid apheresis. The purpose of this review is to discuss the clinical indications and major drawbacks of lipid apheresis in the light of recent evidence.Recent FindingsLipoprotein apheresis should be initiated at early ages and performed frequently to receive the expected cardiovascular benefits. However, in clinical practice, most patients e...
Source: Current Atherosclerosis Reports - February 17, 2021 Category: Cardiology Source Type: research
Trimethylamine N-Oxide (TMAO), Diet and Cardiovascular Disease
AbstractPurpose of ReviewThe association between plasma Trimethylamine N-Oxide (TMAO), diet and risk for cardiovascular disease (CVD) is still not fully understood. While epidemiologic research shows a causal relationship between plasma TMAO concentrations and CVD risk, the role of dietary precursors in determining plasma concentrations of TMAO and biomarkers for CVD is inconclusive.Recent FindingsStudies in diverse populations show that plasma TMAO concentrations are positively associated with inflammation, endothelial dysfunction, type-2 diabetes, central adiposity and hypertension. Most recent studies utilizing challeng...
Source: Current Atherosclerosis Reports - February 17, 2021 Category: Cardiology Source Type: research
